Riboflavin/UVA photochemical therapy for severe infectious keratitis

European Journal of Ophthalmology

Volumn 24, Issue 1, 2013, Pages 21-28

  Skaat, Alon ^a,b   Zadok, David ^b,c   Goldich, Yakov ^b,c   Varssano, David ^d   Berger, Yoav ^a,b   Ezra Nimni, Orit ^a,b   Avni, Isaac ^b,c   Barequet, Irina S ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Collagen crosslinking; Cornea; Infiltrate; Riboflavin; Ultraviolet A light

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CHLORHEXIDINE; COLLAGEN; FLUCONAZOLE; GENTAMICIN; MOXIFLOXACIN; NATAMYCIN; OFLOXACIN; POLY(HEXAMETHYLENEBIGUANIDE); PROPAMIDINE ISETHIONATE; PROSTAGLANDIN DERIVATIVE; RIBOFLAVIN; STEROID; VANCOMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CASE STUDY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; INTERVENTION STUDY; KERATITIS; KERATOCONUS; MIDDLE AGED; NONHUMAN; PENETRATING KERATOPLASTY; PHOTOTHERAPY; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RETROSPECTIVE STUDY; SPECTACLES; STANDARDIZATION; SYMPTOM; THERAPY EFFECT; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; UVA PHOTOCHEMICAL THERAPY; VISUAL ACUITY;

ADULT; AGED; CORNEAL ULCER; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RIBOFLAVIN; SERRATIA INFECTIONS; SERRATIA MARCESCENS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; ULTRAVIOLET RAYS; YOUNG ADULT;

EID: 84889678301     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000330     Document Type: Article

References (33)

1. Ashwin PT, McDonnell PJ. Collagen cross-linkage: a comprehensive review and directions for future research. Br J Ophthalmol 2010;94:965-970.
2. Tsugita A, Okada Y, Uehara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta 1965;103:360-363.
3. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80:15-21.
4. Corbin F III. Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer. Int J Hematol 2002;76(Suppl 2):253-257.
5. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apher-esis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-1341.
6. Makdoumi K, Bäckman A, Mortensen J, Crafoord S. Evaluation of antibacterial efficacy of photo-activated riboflavin using ultraviolet light (UVA). Graefes Arch Clin Exp Ophthalmol 2010;248:207-212.
7. Martins SA, Combs JC, Noguera G, et al. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci 2008;49:3402-3408.
8. Schnitzler E, Spörl E, Seiler T. [Irradiation of cornea with ultraviolet light and riboflavin administration as a new treatment for erosive corneal processes, preliminary results in four patients.]. Klin Monatsbl Augenheilkd 2000;217:190-193.
9. Micelli Ferrari T, Leozappa M, Lorusso M, Epifani E, Micelli Ferrari L. Escherichia coli keratitis treated with ultraviolet A/ riboflavin corneal cross-linking: a case report. Eur J Ophthal-mol 2009;19:295-297.
10. Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea 2008;27:590-594.
11. Khan YA, Kashiwabuchi RT, Martins SA, et al. Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases. Ophthalmology 2011;118:324-331.
12. Kymionis GD, Portaliou DM, Bouzoukis DI, et al. Herpetic keratitis with iritis after corneal crosslinking with riboflavin and ultraviolet A for keratoconus. J Cataract Refract Surg 2007;33:1982-1984.
13. Morén H, Malmsjö M, Mortensen J, Ohrström A. Riboflavin and ultraviolet A collagen crosslinking of the cornea for the treatment of keratitis. Cornea 2010;29:102-104.
14. Spoerl E, Seiler T. Techniques for stiffening the cornea. J Refract Surg 1999;15:711-713.
15. Kashiwabuchi RT, Carvalho FR, Khan YA, et al. Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of Acanthamoeba trophozoites. Invest Ophthalmol Vis Sci 2011;52:9333-9338.
16. Del Buey MA, Cristóbal JA, Casas P, et al. Evaluation of in vitro efficacy of combined riboflavin and ultraviolet a for Acantham-oeba isolates. Am J Ophthalmol 2012;153: 399-404.
17. Garcia-Delpech S, Díaz-Llopis M, Udaondo P, Salom D. Fu-sarium keratitis 3 weeks after healed corneal cross-linking. J Refract Surg 2010;26:994-995.
18. Girgis DO, Karp CL, Miller D. Ocular infections caused by non-tuberculous mycobacteria: update on epidemiology and management. Clin Experiment Ophthalmol 2012;40:467-475.
19. De la Cruz J, Pineda R II. LASIK-associated atypical myco-bacteria keratitis: a case report and review of the literature. Int Ophthalmol Clin 2007;47:73-84.
20. Bottone EJ, Cho KW. Mycobacterium chelonae keratitis: elucidation of diagnosis through evaluation of smears of fluid from patient's contact lens care system. Cornea 2005;24: 356-358.
21. Srinivasan M, Prajna L, Prajna NV. A cluster of cases of My-cobacterium chelonae keratitis following penetrating kerato-plasty. Indian J Ophthalmol 2005;53:67-68.
22. Reviglio V, Rodriguez ML, Picotti GS, et al. Mycobacterium chelonae keratitis following laser in situ keratomileusis. J Refract Surg 1998;14:357-360.
23. Chang MA, Jain S, Azar DT. Infections following laser in situ keratomileusis: an integration of the published literature. Surv Ophthalmol 2004;49:269-280.
24. Karp CL, Tuli SS, Yoo SH, et al. Infectious keratitis after LASIK. Ophthalmology 2003;110:503-510.
25. Solomon A, Karp CL, Miller D, Dubovy SR, Huang AJ, Cul-bertson WW. Mycobacterium interface keratitis after laser in situ keratomileusis. Ophthalmology 2001;108:2201-2208.
26. Freitas D, Alvarenga L, Sampaio J, et al. An outbreak of My-cobacterium chelonae infection after LASIK. Ophthalmology 2003;110:276-285.
27. Brancato R, Carones F, Venturi E, Cavallero A, Gesu G. My-cobacterium chelonae keratitis after excimer laser photore-fractive keratectomy. Arch Ophthalmol 1997;115:1316-1318.
28. Robin JB, Beatty RF, Dunn S, et al. Mycobacterium chelonae keratitis after radial keratotomy. Am J Ophthalmol 1986;102: 72-79.
29. Smiddy WE, Miller D, Flynn HW Jr. Scleral buckle infections due to atypical mycobacteria. Retina 1991;11:394-398.
30. Cosar CB, Cohen EJ, Rapuano CJ, et al. Clear corneal wound infection after phacoemulsification. Arch Ophthalmol 2001;119:1755-1759.
31. Mah-Sadorra J, Cohen EJ, Rapuano CJ. Mycobacterium chelonae wound ulcer after clear-cornea cataract surgery. Arch Ophthalmol 2004;122:1888-1889.
32. Spoerl E, Mrochen M, Sliney D, et al. Safety of UVA-ribofla-vin cross-linking of the cornea. Cornea 2007;26:385-389.
33. Makdoumi K, Mortensen J, Sorkhabi O, et al. UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study. Graefes Arch Clin Exp Ophthalmol 2012;250:95-102.